MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma

Qin,Lifeng; Qin,Jinmei; Lv,Xiaoping; Yin,Caiqiao; Zhang,Qian'e; Zhang,Jiqiao

doi:10.3892/ol.2021.12810

MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma

Authors:
- Lifeng Qin
- Jinmei Qin
- Xiaoping Lv
- Caiqiao Yin
- Qian'e Zhang
- Jiqiao Zhang
View Affiliations

Affiliations: Department of Gastroenterology, Minda Hospital of Hubei Minzu University, Enshi, Hubei 445000, P.R. China, Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: May 24, 2021 https://doi.org/10.3892/ol.2021.12810
Article Number: 549
Copyright: © Qin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. The etiology and pathogenesis of HCC remain unclear. Macrophage migration inhibitory factor (MIF) plays a critical role in the pathogenesis of hepatocellular carcinoma. The association between MIF polymorphisms and its expression level in HCC has rarely been demonstrated. In the present study, the peripheral blood of 202 patients with HCC (HCC group), 242 patients with chronic hepatitis B (CHB group), 215 patients with liver cirrhosis (LC group) and 227 healthy volunteers (normal group) were collected, DNA was extracted and the target fragment of MIF gene was amplified using PCR. The products were then sequenced, and the expression levels of MIF protein were tested using ELISA. The results showed that the MIF rs755622 polymorphism was associated with an increased susceptibility and metastasis of HCC, and that the genotypes GC and CC were associated with poor prognosis of HCC. Compared with the normal, CHB and LC groups, the expression of MIF in the peripheral blood of the HCC group was significantly increased, and the high expression was associated with to poor prognosis. In the HCC group, MIF protein levels for genotypes GC and CC were increased compared with those of genotype GG. The current study indicated that the MIF rs755622 polymorphism is associated with susceptibility and metastasis of HCC, and that the GC and CC genotypes may be indicators of poor prognosis, which may be ascribed to the MIF rs755622 polymorphism leading to elevated MIF protein expression in peripheral blood.

View Figures

View References

1	Kulik L and El-Serag HB: Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 156:477–491.e1. 2019. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Pal LR and Moult J: Genetic basis of common human disease: Insight into the role of missense SNPs from genome-wide association studies. J Mol Biol. 427:2271–2289. 2015. View Article : Google Scholar : PubMed/NCBI
4	Nie S, Wang H and Wang X: Research progress on polymorphism of susceptibility genes in hepatocellular carcinoma. Int J Genet. 41:512–517. 2018.
5	Nobre CC, de Araújo JM, Fernandes TA, Cobucci RN, Lanza DC, Andrade VS and Fernandes JV: Macrophage migration inhibitory factor (MIF): Biological activities and relation with cancer. Pathol Oncol Res. 23:235–244. 2017. View Article : Google Scholar : PubMed/NCBI
6	Grieb G, Merk M, Bernhagen J and Bucala R: Macrophage migration inhibitory factor (MIF): A promising biomarker. Drug News Perspect. 23:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
7	Illescas O, Gomez-Verjan JC, Garcia-Velazquez L, Govezensky T and Rodriguez-Sosa M: Macrophage migration inhibitory factor-173 G/C polymorphism: A global meta-analysis across the disease spectrum. Front Genet. 9:552018. View Article : Google Scholar : PubMed/NCBI
8	Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, et al: Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 51:629–650. 2016. View Article : Google Scholar : PubMed/NCBI
9	Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, et al: Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J Clin Transl Hepatol. 5:297–318. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, et al: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 9:682–720. 2020. View Article : Google Scholar : PubMed/NCBI
11	Forner A, Reig ME, de Lope CR and Bruix J: Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, et al: Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines. Eur J Radiol. 101:72–81. 2018. View Article : Google Scholar : PubMed/NCBI
13	Meza-Romero R, Benedek G, Leng L, Bucala R and Vandenbark AA: Predicted structure of MIF/CD74 and RTL1000/CD74 complexes. Metab Brain Dis. 31:249–255. 2016. View Article : Google Scholar : PubMed/NCBI
14	Jankauskas SS, Wong DWL, Bucala R, Djudjaj S and Boor P: Evolving complexity of MIF signaling. Cell Signal. 57:76–88. 2019. View Article : Google Scholar : PubMed/NCBI
15	Conroy H. Mawhinney L and Donnelly SC: Inflammation and cancer: Macrophage migration inhibitory factor (MIF)-the potential missing link. QJM. 103:831–836. 2010. View Article : Google Scholar : PubMed/NCBI
16	Jäger B, Klatt D, Plappert L, Golpon H, Lienenklaus S, Barbosa PD, Schambach A and Prasse A: CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cell Signal. 73:1096722020. View Article : Google Scholar
17	Guda MR, Rashid MA, Asuthkar S, Jalasutram A, Caniglia JL, Tsung AJ and Velpula KK: Pleiotropic role of macrophage migration inhibitory factor in cancer. Am J Cancer Res. 9:2760–2773. 2019.PubMed/NCBI
18	Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ and Taylor JA: MIF family proteins in genitourinary cancer: Tumorigenic roles and therapeutic potential. Nat Rev Urol. 16:318–328. 2019. View Article : Google Scholar : PubMed/NCBI
19	Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A and Nagasue N: Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer. 103:588–598. 2005. View Article : Google Scholar : PubMed/NCBI
20	Li QT, Feng YM, Ke ZH, Qiu MJ and Xiong ZF: KCNN4 promotes invasion and metastasis through the MAPK/ERK pathway in hepatocellular carcinoma. J Investig Med. 68:68–74. 2019. View Article : Google Scholar : PubMed/NCBI
21	Songlin M, Fei X, Long Y and Yang L: The effect of miRNA-451 on the proliferation and invasion capacity of human hepatocellular carcinoma cell lines via its regulation on COX-2 and other cytokines. Oncol Progress. 16:690–693. 2018.
22	Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F and Todo S: Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 11:1050–1058. 2005.PubMed/NCBI
23	Pei XJ, Wu TT, Li B, Tian XY, Li Z and Yang QX: Increased expression of macrophage migration inhibitory factor and DJ-1 contribute to cell invasion and metastasis of nasopharyngeal carcinoma. Int J Med Sci. 11:106–115. 2014. View Article : Google Scholar : PubMed/NCBI
24	Liu J, Zhang C, Hu W and Feng Z: Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 356:197–203. 2015. View Article : Google Scholar : PubMed/NCBI
25	Mathumai K: Treating p53 mutant aggregation-associated cancer. Cancers. 10:1542018. View Article : Google Scholar
26	Ubby I, Krueger C, Rosato R, Qian W, Chang J and Sabapathy K: Cancer therapeutic targeting using mutant-p53-specific siRNAs. Oncogene. 38:3415–3427. 2019. View Article : Google Scholar : PubMed/NCBI
27	Fukaya R, Ohta S, Yaguchi T, Matsuzaki Y, Sugihara E, Okano H, Saya H, Kawakami Y, Kawase T, Yoshida K and Toda M: MIF maintains the tumorigenic capacity of brain tumor-initiating cells by directly inhibiting p53. Cancer Res. 76:2813–2823. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kong F, Xuan D, Kong X, Du Y, Li L, Zhu H, Wang Y, Xie D, Guha S, Li Z, et al: ZFPM2-AS1, a Novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 37:5982–5996. 2018. View Article : Google Scholar : PubMed/NCBI
29	Ramireddy L, Chen WT, Peng CT, Hu RM, Ke TW, Chiang HC, Chang SC, Tsai FJ and Lo WY: Association between genetic polymorphism of the MIF gene and colorectal cancer in Taiwan. J Clin Lab Anal. 29:268–274. 2015. View Article : Google Scholar : PubMed/NCBI
30	Lin S, Wang M, Liu X, Zhu W, Guo Y, Dai Z, Yang P, Tian T, Dai C, Zheng Y, et al: Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women. Clin Exp Med. 17:395–401. 2017. View Article : Google Scholar : PubMed/NCBI
31	Ding GX, Zhou SQ, Xu Z, Feng NH, Song NH, Wang XJ, Yang J, Zhang W, Wu HF and Hua LX: The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese. J Surg Oncol. 100:106–110. 2009. View Article : Google Scholar : PubMed/NCBI
32	Xiang T, Bing Z, Tong Q, Liu S, Peng S, Yang X and Fan H: The MIF-173G/C gene polymorphism increase gastrointestinal cancer and hematological malignancy risk: Evidence from a meta-analysis and FPRP test. Int J Clin Exp Med. 8:15949–15957. 2015.PubMed/NCBI
33	Yuan T, Tang C, Chen M, Deng S and Chen P: Influence of the human MIF promoter polymorphism on hepatocellular carcinoma prognosis. Genet Mol Res. 12:6629–6635. 2013. View Article : Google Scholar : PubMed/NCBI
34	O'Reilly C, Doroudian M, Mawhinney L and Donnelly SC: Targeting MIF in cancer: Therapeutic strategies, current developments, and future opportunities. Med Res Rev. 36:440–460. 2016. View Article : Google Scholar
35	Wang D, Luo L, Chen W, Chen LZ, Zeng WT, Li W and Huang XH: Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 31:1199–1204. 2014. View Article : Google Scholar : PubMed/NCBI
36	Zhao YM, Wang L, Dai Z, Wang DD, Hei ZY, Zhang N, Fu XT, Wang XL, Zhang SC, Qin LX, et al: Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int J Cancer. 129:2463–2472. 2011. View Article : Google Scholar : PubMed/NCBI
37	Han Y and Zhang C: Macrophage migration inhibitory factor plays a pivotal role in hepatocellular carcinoma and may be a noninvasive imaging target. Medical Hypotheses. 75:530–532. 2010. View Article : Google Scholar : PubMed/NCBI
38	Oscar I, Gomez-Verjan JC, Lizbeth GV, Tzipe G and Miriam RS: Macrophage migration inhibitory factor-173 G/C polymorphism: A global meta-analysis across the disease spectrum. Front Genet. 9:552018. View Article : Google Scholar
39	Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, Lupo L, Faloppi L, Palasciano G, Memeo V, et al: Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 19:1623–1635. 2015. View Article : Google Scholar : PubMed/NCBI
40	Zhang K, Pan X, Shu X, Cao H, Chen L, Zou Y, Deng H, Li G and Xu Q: Relationship between MIF-173 G/C polymorphism and susceptibility to chronic hepatitis B and HBV-induced liver cirrhosis. Cell Immunol. 282:113–116. 2013. View Article : Google Scholar : PubMed/NCBI